Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission

BACKGROUND: Bowel urgency reduces ulcerative colitis patients' quality of life. Mirikizumab, a p19-directed anti-IL-23 antibody, demonstrates ulcerative colitis efficacy. Mirikizumab efficacy to reduce bowel urgency and bowel urgency association with other endpoints were analyzed in 2 Phase 3 t...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubinsky, Marla C, Clemow, David B, Hunter Gibble, Theresa, Li, Xingyuan, Vermeire, Severine, Hisamatsu, Tadakazu, Travis, Simon P L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802448/
https://www.ncbi.nlm.nih.gov/pubmed/36777368
http://dx.doi.org/10.1093/crocol/otac044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802448/
https://www.ncbi.nlm.nih.gov/pubmed/36777368
http://dx.doi.org/10.1093/crocol/otac044

Ejemplares similares